{"type":"trials","record":{"id":41938,"source_id":"clinicaltrials-gov","external_id":"NCT06046118","title":"Photobiomodulation in Dry Age Related Macular Degeneration","brief_summary":"The goal of this clinical trial is to evaluate effects of consecutive Yellow and Red Light Emitting Diode photobiomodulation in dry age-related macular degeneration (AMD). The main questions it aims to answer are: * Is Yellow and Red Light Emitting Diode photobiomodulation effective in decreasing drusen volume in patients affected by dry AMD? * Does Yellow and Red Light Emitting Diode photobiomodulation increase visual acuity and contrast sensitivity in patients affected by dry AMD? Participants will be randomly assigned to a treatment or a sham group. Treatment consists in two cycles with two phases each: * 1st phase: 300 seconds of continuous Yellow light with eyes closed + 60 seconds of pulsed Yellow light with eyes opened; * 2d phase: 300 seconds of continuous Red light with eyes closed + 60 seconds of pulsed Red light with eyes opened. Cycle 1 consists of 8 sessions (two PBM per week for 4 weeks) and cycle 2 consists of 6 sessions (two PBM per week for 3 weeks). Researchers will compare patients in the treatment group to those in the sham group to evaluate differences in objective signs and subjective symptoms of dry AMD.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Azienda Ospedaliera Universitaria Mater Domini, Catanzaro","enrollment":180,"countries":["France","Italy","Turkey (Türkiye)","United Kingdom"],"start_date":"2023-04-01","completion_date":"2024-12-31","last_update_date":"2024-09-19","source_url":"https://clinicaltrials.gov/study/NCT06046118","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"DRUSEN","age_range":"50 Years","comparator":null,"organization":"Azienda Ospedaliera Universitaria Mater Domini, Catanzaro","interventions":["Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)","Sham Mask"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best Corrected Visual Acuity variation — 1 month, 2 months and 4 months after each cycle","Drusen Volume Variation — 1 month, 2 months and 4 months after each cycle","Contrast sensitivity variation — 1 month, 2 months and 4 months after each cycle"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)","Sham Mask"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06046118","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-04-01 to 2024-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.895Z","intervention":["Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)","Sham Mask"],"participants":180,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best Corrected Visual Acuity variation — 1 month, 2 months and 4 months after each cycle","Drusen Volume Variation — 1 month, 2 months and 4 months after each cycle","Contrast sensitivity variation — 1 month, 2 months and 4 months after each cycle"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41938","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}